OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical, Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) today announced that the U.S. Food and Drug Administration ...
Patients with TGCT are encouraged to honestly discuss their pain with their care teams. Patients with TGCTs, or tenosynovial giant cell tumors, often have to deal with pain and discomfort as a result ...
Vimseltinib is the first and only therapy with a positive CHMP opinion for the treatment of TGCT in the European Union OSAKA, Japan & WALTHAM, Mass., July 28, 2025--(BUSINESS WIRE)--Deciphera ...
An Ono Pharma drug for a type of tumor affecting tissues of the joints is now FDA approved, giving the Japanese company a product with dosing and safety advantages over the Daiichi Sankyo product that ...
- If approved by the FDA, pexidartinib would be the first and only approved therapy for tenosynovial giant cell tumor (TGCT) when associated with severe morbidity or functional limitations, and not ...
Ono Pharmaceutical has secured approval from the US Food and Drug Administration (FDA) for its kinase inhibitor Romvimza (vimseltinib) to treat tenosynovial giant cell tumour (TGCT), introducing ...
Tenosynovial giant cell tumor (TGCT) is a condition in which tumors form in the tissues of joints, causing pain and swelling in the affected area. It can be difficult to stay active if you have TGCT, ...
Ono Pharmaceutical has claimed FDA approval for Romvimza as a treatment for tenosynovial giant cell tumour (TGCT), setting up a market tussle with Daiichi Sankyo. CSF-1R inhibitor Romvimza ...
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue that ...
Watch a webinar as experts on tenosynovial giant cell tumor (TGCT) share an overview of TGCT and a simple summary of the MOTION study. ROMVIMZA is a prescription medicine used to treat adults with ...
OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results